Scotia Capital’s GoodRx Holdings GDRX Stock Holding History

Scotia Capital’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-6,257	Closed	-$244K	–	847
2021 Q1	$244K	Buy	+6,257	New	+$281K	﹤0.01%	721

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Atreides Management Boston, Massachusetts $5B AUM 78.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tiger Global Management New York $22.8B AUM 30.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

Scotia Capital's GDRX Position: Q2 2021 in Review

Scotia Capital sold out of GoodRx Holdings (GDRX) in Q2 2021, closing a stake of 6,257 shares — an estimated $244K sold.

Scotia Capital first reported a position in GDRX in Q1 2021 and held it in 1 quarter. The position peaked at $244K in Q1 2021. 199 funds tracked by Wall St. Rank hold GDRX as of Q2 2021.

Scotia Capital reported no remaining GoodRx Holdings position as of Q2 2021 after selling out during the quarter.
Scotia Capital sold 6,257 GoodRx Holdings shares in Q2 2021, an estimated $244K.
Scotia Capital first reported a position in GoodRx Holdings in Q1 2021 and held it in 1 quarter.
Scotia Capital's GoodRx Holdings position peaked at $244K in Q1 2021.
199 funds tracked by Wall St. Rank held GoodRx Holdings as of Q2 2021.

Based on Scotia Capital's 13F filing for Q2 2021, filed 12 Aug 2021.